«Under current law, the FDA faces a high burden before it can take enforcement
action on a dietary supplement,» wrote spokeswoman Lyndsay Meyer in an email message.
The therapeutic dotential of
dietary precursor modulation by a fish - oil -
supplemented diet (n - 3 fatty acids), such as eicosapentaenoic acid (C20: 5,n - 3) and docosahexaenoic acid (C22: 6,n - 3) in the therapy of ulcerative colitis has been shown to result in a 35 % to 50 % decrease in neutrophil production of LTB4.28 Significant improvement in symptoms and histologic appearance of the rectal mucosa has been observed in several small series of patients with Crohn's disease and ulcerative colitis given fish oil at 3 to 4 g daily for 2 to 6 months in uncontrolled studies.29 However, a larger, randomized, double - blind trial comprising 96 patients with ulcerative colitis failed to reveal any benefit in remission maintenance or treatment of relapse
on 4.5 g of eicosapentaenoic acid daily, despite a significant reduction in LTB4 synthesis by blood peripheral polymorphonuclear cells.30 It should be emphasized, however, that the anti-inflammatory
actions of the fish oils, in addition to inhibition of LTB4, include suppression of IL - 1 and platelet activating factor synthesis and scavenging of free oxygen radicals.30 The impact of increased lipid peroxidation after fish oil supplementation should be considered when altering the n - 6: n - 3 fatty acid ratio.31 Antioxidant supplementation may be able to counteract the potentially adverse effects of n - 3 fatty acids.
Our members have handled hundreds of jury trials, mass
actions and class
actions on behalf of leading manufacturers that operate in a wide variety of industries, including automotive; tobacco; pharmaceutical and medical device; chemical; sports equipment; aviation; and food,
dietary supplement, and personal care products.